Leading the Vanguard – Early Clinical Assessment of Biomarkers to Drive Development of Alzheimer’s Disease Therapies

Time: 3:00 pm
day: Day Two

Details:

  • Building a translational strategy to identify robust preclinical signals
  • Interrogating biomarkers by applying a translational pharmacology approach in Phase 1
  • Capitalizing on objective assessments to guide clinical development in early patient studies

Speakers: